Reimbursed Care Access in Niue

Currently classified as a strictly controlled substance under international and typical national drug-scheduling frameworks, with no authorised medical use in Niue outside of approved clinical research. The 1971 UN Convention on Psychotropic Substances lists classical tryptamines (including psilocybin/psilocin) under international controls, a framework Niue implements as a party to multilateral drug-control mechanisms; thus domestic legal access for psilocybin for routine medical treatment or reimbursement is not available. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use in Niue outside of approved clinical research. MDMA is controlled under the 1971 Convention on Psychotropic Substances, and Niue follows international obligations that do not provide for routine medical/reimbursed MDMA therapy in-country. # #.

Esketamine (Spravato) does not have an established, reimbursed availability in Niue. There is no public evidence of Medsafe‑style regulatory approvals or domestic reimbursement decisions for esketamine in Niue; esketamine product authorisations have been progressed in nearby New Zealand (distribution consent for Spravato in New Zealand is documented), but such New Zealand authorisations do not equate to automatic availability or public funding in Niue. Therefore routine reimbursed access in Niue should be considered unavailable; any use would require import/exception pathways or treatment received off‑island. # #.

Niue’s health services use standard essential medicines for clinical care (ketamine is on the WHO Model List of Essential Medicines as an injectable anaesthetic), so ketamine is available and used within the health system primarily for anaesthesia and emergency medicine rather than as an on‑label reimbursed psychiatric medicine. The WHO country page for Niue documents a functioning health service and hospital pharmacy infrastructure where essential medicines are provided. # #.

Off‑label psychiatric use (intravenous or intranasal ketamine infusions for depression) would, if it occurs, be delivered under clinical discretion and is not known to be part of any publicly funded/reimbursed mental‑health programme in Niue. There is no public record of an esketamine‑style, regulated, reimbursed psychiatric programme operating in Niue; patients seeking esketamine or off‑label ketamine for mood disorders would typically need treatment through private arrangements or travel to jurisdictions (e.g., New Zealand) where regulatory pathways and private clinics exist. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use in Niue outside of approved clinical research. DMT is controlled under international psychotropic substance schedules, and there is no evidence of an authorised therapeutic or reimbursed pathway in Niue. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use in Niue outside of approved clinical research. There is no indication of an authorised medical or reimbursed programme for 5‑MeO‑DMT in Niue. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use in Niue outside of approved clinical research. Niue has no documented medical or reimbursed ibogaine programmes; use would be restricted to approved research if any domestic framework exists. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use in Niue outside of approved clinical research. Although ayahuasca is a traditional plant brew rather than a single chemical, its principal psychoactive constituent (DMT) is internationally controlled; Niue does not have an established, reimbursed pathway for ritual or medical ayahuasca use. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use in Niue outside of approved clinical research. Mescaline and mescaline‑containing cacti are subject to international psychotropic controls and there is no evidence of medical/reimbursed access in Niue. # #.

Currently classified as a strictly controlled substance (or covered under analogue/NPS rules) under national drug scheduling laws, with no authorized medical use in Niue outside of approved clinical research. Substituted phenethylamines such as the 2C family are generally controlled internationally or via domestic analogue provisions; Niue does not have an authorised or reimbursed medical pathway for 2C‑X compounds. # #.